Cargando…

Genetic Influences in Breast Cancer Drug Resistance

Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacothera...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniyal, Adhitiya, Santoso, Ivana, Gunawan, Nadira Hasna Putri, Barliana, Melisa Intan, Abdulah, Rizky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882715/
https://www.ncbi.nlm.nih.gov/pubmed/33603458
http://dx.doi.org/10.2147/BCTT.S284453
_version_ 1783651103436439552
author Daniyal, Adhitiya
Santoso, Ivana
Gunawan, Nadira Hasna Putri
Barliana, Melisa Intan
Abdulah, Rizky
author_facet Daniyal, Adhitiya
Santoso, Ivana
Gunawan, Nadira Hasna Putri
Barliana, Melisa Intan
Abdulah, Rizky
author_sort Daniyal, Adhitiya
collection PubMed
description Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacotherapy is based on the characteristics of the tumor and its hormone receptor status, specifically, the presence of HER2, progesterone receptors, and estrogen receptors. Breast cancer pharmacotherapy often gives different results in various populations, which may cause therapeutic failure. Different types of congenital drug resistance in individuals can cause this. Genetic polymorphism is a factor in the occurrence of congenital drug resistance. This review explores the relationship between genetic polymorphisms and resistance to breast cancer therapy. It considers studies published from 2010 to 2020 concerning the relationship of genetic polymorphisms and breast cancer therapy. Several gene polymorphisms are found to be related to longer overall survival, worse relapse-free survival, higher pathological complete response, and increased disease-free survival in breast cancer patients. The presence of these gene polymorphisms can be considered in the treatment of breast cancer in order to shape personalized therapy to yield better results.
format Online
Article
Text
id pubmed-7882715
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78827152021-02-17 Genetic Influences in Breast Cancer Drug Resistance Daniyal, Adhitiya Santoso, Ivana Gunawan, Nadira Hasna Putri Barliana, Melisa Intan Abdulah, Rizky Breast Cancer (Dove Med Press) Review Breast cancer is the most common cancer in adult women aged 20 to 50 years. The therapeutic regimens that are commonly recommended to treat breast cancer are human epidermal growth factor receptor 2 (HER2) targeted therapy, endocrine therapy, and systemic chemotherapy. The selection of pharmacotherapy is based on the characteristics of the tumor and its hormone receptor status, specifically, the presence of HER2, progesterone receptors, and estrogen receptors. Breast cancer pharmacotherapy often gives different results in various populations, which may cause therapeutic failure. Different types of congenital drug resistance in individuals can cause this. Genetic polymorphism is a factor in the occurrence of congenital drug resistance. This review explores the relationship between genetic polymorphisms and resistance to breast cancer therapy. It considers studies published from 2010 to 2020 concerning the relationship of genetic polymorphisms and breast cancer therapy. Several gene polymorphisms are found to be related to longer overall survival, worse relapse-free survival, higher pathological complete response, and increased disease-free survival in breast cancer patients. The presence of these gene polymorphisms can be considered in the treatment of breast cancer in order to shape personalized therapy to yield better results. Dove 2021-02-09 /pmc/articles/PMC7882715/ /pubmed/33603458 http://dx.doi.org/10.2147/BCTT.S284453 Text en © 2021 Daniyal et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Daniyal, Adhitiya
Santoso, Ivana
Gunawan, Nadira Hasna Putri
Barliana, Melisa Intan
Abdulah, Rizky
Genetic Influences in Breast Cancer Drug Resistance
title Genetic Influences in Breast Cancer Drug Resistance
title_full Genetic Influences in Breast Cancer Drug Resistance
title_fullStr Genetic Influences in Breast Cancer Drug Resistance
title_full_unstemmed Genetic Influences in Breast Cancer Drug Resistance
title_short Genetic Influences in Breast Cancer Drug Resistance
title_sort genetic influences in breast cancer drug resistance
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882715/
https://www.ncbi.nlm.nih.gov/pubmed/33603458
http://dx.doi.org/10.2147/BCTT.S284453
work_keys_str_mv AT daniyaladhitiya geneticinfluencesinbreastcancerdrugresistance
AT santosoivana geneticinfluencesinbreastcancerdrugresistance
AT gunawannadirahasnaputri geneticinfluencesinbreastcancerdrugresistance
AT barlianamelisaintan geneticinfluencesinbreastcancerdrugresistance
AT abdulahrizky geneticinfluencesinbreastcancerdrugresistance